Literature DB >> 35815178

New-Onset Psychotic Symptoms Following Abrupt Buprenorphine/Naloxone Discontinuation in a Female Patient with Bipolar Disorder: A Case Report.

Yezhe Lin1, Alexander D Zhang1, Ching-Fang Sun1, Justin B White1, Ansi Qi1, Jessica A Farrell1, Robert L Trestman1, Rachel K Martin1, Anita S Kablinger1.   

Abstract

Buprenorphine and naloxone (Suboxone) is a combination medication-assisted treatment (MAT) for opioid use disorder. MAT withdrawal-induced psychosis is a rare clinical presentation. To our best knowledge, only three reports have summarized the characteristic manifestations of buprenorphine withdrawal psychosis, yet all of them were male. In this case report, we present a 41-year-old female patient with bipolar disorder and comorbid substance use disorder who developed new-onset psychosis and relapse of manic symptoms following abrupt discontinuation of Suboxone. Manic and psychotic symptoms remitted after a short-term hospitalization with the treatment of an antipsychotic and a mood stabilizer. In addition to discussing this case presentation and treatment approach, we review existing literature and discuss possible underlying mechanisms to enhance understanding of this clinical phenomenon.
Copyright © 1964–2022 by MedWorks Media Inc, Los Angeles, CA All rights reserved. Printed in the United States.

Entities:  

Keywords:  buprenorphine; mania; psychosis; substance-withdrawal; two-hit hypothesis

Mesh:

Substances:

Year:  2022        PMID: 35815178      PMCID: PMC9235316     

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  16 in total

1.  Possible manic potential of buprenorphine.

Authors:  Karuppiah Jagadheesan; David Muirhead
Journal:  Aust N Z J Psychiatry       Date:  2004-07       Impact factor: 5.744

Review 2.  Opioid use and schizophrenia.

Authors:  Kevin J Li; Anderson Chen; Lynn E DeLisi
Journal:  Curr Opin Psychiatry       Date:  2020-05       Impact factor: 4.741

3.  Possible Psychosis Associated With Buprenorphine Withdrawal.

Authors:  Praveen Navkhare; Gurvinder Kalra; Sahoo Saddichha
Journal:  J Clin Psychopharmacol       Date:  2017-12       Impact factor: 3.153

4.  Possible antidepressive effects of opioids: action of buprenorphine.

Authors:  H M Emrich; P Vogt; A Herz
Journal:  Ann N Y Acad Sci       Date:  1982       Impact factor: 5.691

5.  Antipsychotic effect of buprenorphine in schizophrenia.

Authors:  C Schmauss; A Yassouridis; H M Emrich
Journal:  Am J Psychiatry       Date:  1987-10       Impact factor: 18.112

6.  Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine.

Authors:  D S Harris; R T Jones; S Welm; R A Upton; E Lin; J Mendelson
Journal:  Drug Alcohol Depend       Date:  2000-12-22       Impact factor: 4.492

7.  Young Mania Rating Scale: how to interpret the numbers? Determination of a severity threshold and of the minimal clinically significant difference in the EMBLEM cohort.

Authors:  Michael Lukasiewicz; Stephanie Gerard; Adeline Besnard; Bruno Falissard; Elena Perrin; Helene Sapin; Mauricio Tohen; Catherine Reed; Jean-Michel Azorin
Journal:  Int J Methods Psychiatr Res       Date:  2013-03-21       Impact factor: 4.035

8.  A Population-Based Cohort Study Examining the Incidence and Impact of Psychotic Experiences From Childhood to Adulthood, and Prediction of Psychotic Disorder.

Authors:  Sarah A Sullivan; Daphne Kounali; Mary Cannon; Anthony S David; Paul C Fletcher; Peter Holmans; Hannah Jones; Peter B Jones; David E J Linden; Glyn Lewis; Michael J Owen; Michael O'Donovan; Alexandros Rammos; Andrew Thompson; Dieter Wolke; Jon Heron; Stanley Zammit
Journal:  Am J Psychiatry       Date:  2020-01-07       Impact factor: 18.112

9.  Prescription Opioid Use, Misuse, and Use Disorders in U.S. Adults: 2015 National Survey on Drug Use and Health.

Authors:  Beth Han; Wilson M Compton; Carlos Blanco; Elizabeth Crane; Jinhee Lee; Christopher M Jones
Journal:  Ann Intern Med       Date:  2017-08-01       Impact factor: 25.391

10.  Psychosis after buprenorphine, heroin, methadone, morphine, oxycodone, and tramadol withdrawal: a systematic review.

Authors:  M T Lozano-López; S Gamonal-Limcaoco; N Casado-Espada; L Aguilar; B Vicente-Hernández; L Grau-López; A Álvarez-Navares; C Roncero
Journal:  Eur Rev Med Pharmacol Sci       Date:  2021-07       Impact factor: 3.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.